Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Giredestrant will soon become the first oral SERD to yield first-line data.
But this adds another complexity, and has camizestrant really scored a first-line win?
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
A key pivotal study of bemarituzumab will read out shortly.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
